Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.

ABSTRACT:

Objective

To present the interim findings from a national study investigating the safety and efficacy of convalescent plasma (CP) containing detectable IgG antibodies as a treatment strategy for severe coronavirus disease 2019 (COVID-19).

Trial design and participants

An open label, two-arm, phase-II clinical trial conducted across 22 hospitals from Saudi Arabia. The intervention group included 40 adults (aged ≥18 years) with confirmed severe COVID-19 and the control group included 124 patients matched using propensity score for age, gender, intubation status, and history of diabetes and/or hypertension. Intervention group included those (a) with severe symptoms (dyspnea; respiratory rate, ≥30/min; SpO₂, ≤93%, PaO2/FiO2 ratio, <300; and/or lung infiltrates >50% wi

SUBMITTER: AlShehry N 

PROVIDER: S-EPMC7839574 | biostudies-literature | 2021 Jan-Apr

REPOSITORIES: biostudies-literature